Skip to main content
. 2019 Jul 19;8(11):5108–5115. doi: 10.1002/cam4.2418

Figure 1.

Figure 1

Enrollment and outcomes in patients with decitabine treatment. Abbreviations: AML, acute myeloid leukemia; CAG, Cytarabine + Aclarubicin +G‐CSF; CR, complete remission; DAC, Decitabine; FLAG, Fludarabine + Cytarabine +G‐CSF; HAA/HAG, Homoharringtonine + Cytarabine +Aclarubicin/ Granulocyte Colony‐Stimulating Factor (G‐CSF); IA, Idarubicin + Cytarabine; MAE/IAE, Mitoxantrone/ Idarubicin (MA) + Cytarabine + Etoposide); MDS, myelodysplasia syndrome; PR, partial remission